Treatment Innovations

Aardvark Therapeutics Faces Existential Crossroads Following Clinical Hold on Lead Asset ARD-101

• Treatment Innovations

Aardvark Therapeutics Faces Existential Crossroads Following Clinical Hold on Lead Asset ARD-101

Ammar Sabilarrohman May 15, 2026 0

By Jonathan Gardner | BioPharma Dive Published May 15, 2026 In a development that has sent shockwaves...

Read More Read more about Aardvark Therapeutics Faces Existential Crossroads Following Clinical Hold on Lead Asset ARD-101

The GLP-1 Paradox: Pharmaceutical R&D Productivity Rebounds, But at What Cost?

• Treatment Innovations

The GLP-1 Paradox: Pharmaceutical R&D Productivity Rebounds, But at What Cost?

Laily UPN May 15, 2026 0

After years of grappling with declining R&D returns and the "post-pandemic hangover," the global biopharmaceutical sector has...

Read More Read more about The GLP-1 Paradox: Pharmaceutical R&D Productivity Rebounds, But at What Cost?

Butterfly Medical Secures $21M Series C Funding as Pivotal BPH Trial Concludes

• Treatment Innovations

Butterfly Medical Secures $21M Series C Funding as Pivotal BPH Trial Concludes

Laily UPN May 15, 2026 0

In a significant stride for urological healthcare, Butterfly Medical has announced the successful completion of its pivotal...

Read More Read more about Butterfly Medical Secures $21M Series C Funding as Pivotal BPH Trial Concludes

Rivermark Medical Secures $20 Million Series D to Advance Minimally Invasive BPH Treatment

• Treatment Innovations

Rivermark Medical Secures $20 Million Series D to Advance Minimally Invasive BPH Treatment

Dwi Wanna May 15, 2026 0

Wisconsin-based medical technology firm Rivermark Medical has announced the successful closure of a $20 million Series D...

Read More Read more about Rivermark Medical Secures $20 Million Series D to Advance Minimally Invasive BPH Treatment

Revvity Bolsters Endocrine Diagnostics: FDA Clears Automated Total Testosterone Assay

• Treatment Innovations

Revvity Bolsters Endocrine Diagnostics: FDA Clears Automated Total Testosterone Assay

Laily UPN May 15, 2026 0

In a significant advancement for clinical endocrinology, Revvity has secured US Food and Drug Administration (FDA) clearance...

Read More Read more about Revvity Bolsters Endocrine Diagnostics: FDA Clears Automated Total Testosterone Assay

Navigating the Tightrope: Regenxbio’s Bid for Duchenne Gene Therapy Approval Amid Regulatory Flux

• Treatment Innovations

Navigating the Tightrope: Regenxbio’s Bid for Duchenne Gene Therapy Approval Amid Regulatory Flux

Suro Senen May 15, 2026 0

By Ben Fidler | May 14, 2026 The race to redefine treatment for Duchenne muscular dystrophy (DMD)...

Read More Read more about Navigating the Tightrope: Regenxbio’s Bid for Duchenne Gene Therapy Approval Amid Regulatory Flux

The Great Pivot: BioNTech’s Strategic Exit from Infectious Disease and Return to Oncology Roots

• Treatment Innovations

The Great Pivot: BioNTech’s Strategic Exit from Infectious Disease and Return to Oncology Roots

Laily UPN May 14, 2026 0

The global biotechnology landscape is witnessing a seismic shift as German mRNA pioneer BioNTech, once the face...

Read More Read more about The Great Pivot: BioNTech’s Strategic Exit from Infectious Disease and Return to Oncology Roots

Breakthrough in Urological Oncology: AngioDynamics Reports Positive Two-Year Data for NanoKnife IRE System

• Treatment Innovations

Breakthrough in Urological Oncology: AngioDynamics Reports Positive Two-Year Data for NanoKnife IRE System

Suro Senen May 14, 2026 0

In a significant development for the field of urological oncology, medical technology firm AngioDynamics has announced promising...

Read More Read more about Breakthrough in Urological Oncology: AngioDynamics Reports Positive Two-Year Data for NanoKnife IRE System

Create Medicines Secures $122M Series B to Pioneer “In Vivo” CAR-T Revolution

• Treatment Innovations

Create Medicines Secures $122M Series B to Pioneer “In Vivo” CAR-T Revolution

Ali Ikhwan May 14, 2026 0

By Delilah Alvarado | May 14, 2026 In a significant vote of confidence for the next generation...

Read More Read more about Create Medicines Secures $122M Series B to Pioneer “In Vivo” CAR-T Revolution

UroMems Secures $60M Funding Milestone to Accelerate Breakthrough in Stress Urinary Incontinence Treatment

• Treatment Innovations

UroMems Secures $60M Funding Milestone to Accelerate Breakthrough in Stress Urinary Incontinence Treatment

Rifan Muazin May 14, 2026 0

In a significant move that promises to reshape the landscape of urological care, French medtech innovator UroMems...

Read More Read more about UroMems Secures $60M Funding Milestone to Accelerate Breakthrough in Stress Urinary Incontinence Treatment